IMR Press / FBL / Volume 20 / Issue 7 / DOI: 10.2741/4365

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Review
MMP Inhibitors: Past, present and future
Show Less
1 Department of Pharmacology, Stony Brook University, Stony Brook, NY 11794, USA
2 Department of Medicine, Stony Brook University, Stony Brook, NY 11794, USA
Academic Editor:Jian Cao
Front. Biosci. (Landmark Ed) 2015, 20(7), 1164–1178; https://doi.org/10.2741/4365
Published: 1 June 2015
(This article belongs to the Special Issue Matrix metalloproteinases in diseases)
Abstract

Development of inhibitors of (MMPs) has been fraught with challenges. Early compounds largely failed due to poor selectivity and bioavailability. Dose-limiting side effects, off-target interactions, and improperly designed clinical trials significantly impeded clinical success. As information becomes available and technology evolves, tools to combat these obstacles have been developed. Improved methods for high throughput screening and drug design have led to identification of compounds exhibiting high potency, binding affinity, and favorable pharmacokinetic profiles. Current research into MMP inhibitors employs innovative approaches for drug delivery methods and allosteric inhibitors. Such innovation is key for development of clinically successful compounds.

Keywords
Matrix Metalloproteinases
MMP
MMP inhibitor
Review
Share
Back to top